Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
55.60-0.17 (-0.30%)
At close: 04:00PM EDT
55.60 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close55.77
Open54.50
Bid55.15 x 800
Ask55.92 x 1300
Day's Range54.35 - 56.41
52 Week Range45.20 - 104.38
Volume677,727
Avg. Volume690,187
Market Cap3.894B
Beta (5Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RARE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ultragenyx Pharmaceutical Inc.
    Daily – Vickers Top Buyers & Sellers for 04/20/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Zacks

    Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

    Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

  • Benzinga

    Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance

    Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Q2 sales reached $89.3 million, up from $86.97 million a year ago, beating the consensus of $87.51 million. The company recognized $64.0 million in Crysvita (burosumab) revenue in the Ultragenyx territories, including $51.6 million in collaboration revenue in the North American profit share territory and net product sales in other territories regions of $12.4 million. Yoyalty revenue related to European Crysvita sales was $5.4 million. Dojolvi's (tr

  • Zacks

    Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

    Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement